Pain Management & Rehab Consult
Pain Management & Rehab Consult was paid $570K by Medicaid between Jan 2018 and Nov 2024, across 54 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 37% of everything it billed.
33Billing provider infoPAIN MANAGEMENT & REHAB CONSULT
FAYETTEVILLE, AR 72703
FAYETTEVILLE, AR 72703
33aNPI1396783338assigned 06/03/2006
33bProvider typeSpecialist
28Total paid$570K
24GClaims37,613
24DCodes billed54
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Specialist providers in Arkansas
Rank by total paid#24 of 123
Median peer was paid$38K
This provider vs. median15×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,955 | $138K | |
| 2019 | 5,704 | $76K | |
| 2020 | 3,839 | $50K | |
| 2021 | 5,394 | $87K | |
| 2022 | 5,720 | $81K | |
| 2023 | 5,289 | $77K | |
| 2024incomplete | 3,712 | $61K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 37% | 7,696 | 6,705 | $210K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 12% | 6,607 | 5,763 | $70K |
| 99152 | 7.1% | 2,085 | 1,761 | $41K | |
| 64635 | 6.2% | 88 | 72 | $35K | |
| 64493 | 5.1% | 426 | 354 | $29K | |
| 64636 | 2.7% | 65 | 60 | $16K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.6% | 1,088 | 860 | $15K |
| 80354 | 2.1% | 595 | 515 | $12K | |
| 80373 | 2.1% | 593 | 515 | $12K | |
| 80365 | 2.0% | 593 | 515 | $11K | |
| 64494 | 1.9% | 425 | 353 | $11K | |
| 80348 | 1.8% | 541 | 465 | $10K |
42 more codes
| 62323 | 1.7% | 84 | $10K | |
| 80369 | 1.3% | 352 | $7K | |
| 80362 | 1.2% | 352 | $7K | |
| 80356 | 1.2% | 301 | $7K | |
| 80367 | 1.2% | 537 | $7K | |
| 80323 | 1.1% | 282 | $6K | |
| 99215 | Doctor's office visit, returning patient (complex) | 1.1% | 130 | $6K |
| 80358 | <1% | 300 | $6K | |
| 80372 | <1% | 301 | $5K | |
| 80355 | <1% | 352 | $5K | |
| 80335 | <1% | 300 | $5K | |
| 80346 | <1% | 224 | $4K | |
| 80366 | <1% | 301 | $4K | |
| 80363 | <1% | 223 | $4K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 476 | $4K |
| 80324 | <1% | 225 | $3K | |
| 80349 | <1% | 211 | $3K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 230 | $918.15 |
| 99205 | Prolong outpt/office vis | <1% | 19 | $912.01 |
| 80359 | <1% | 41 | $731.55 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 20 | $677.78 |
| 80357 | <1% | 41 | $425.92 | |
| 80350 | <1% | 41 | $298.48 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,830 | $229.25 |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 1,265 | $167.23 |
| 83992 | <1% | 33 | $159.36 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 337 | $115.52 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,706 | $71.14 |
| 80345 | <1% | 41 | $60.42 | |
| 80338 | <1% | 41 | $58.46 | |
| 80371 | <1% | 41 | $55.62 | |
| 80360 | <1% | 41 | $45.92 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 403 | $42.47 |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 1,806 | $14.41 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 786 | $3.59 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 13 | $2.02 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 0% | 122 | $0.00 |
| 1125F | 0% | 2,600 | $0.00 | |
| 96132 | 0% | 66 | $0.00 | |
| G0444 | Annual depression screening, 5 to 15 minutes | 0% | 192 | $0.00 |
| 96138 | 0% | 128 | $0.00 | |
| 76000 | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHARP, FELISHA (OFFICE MANAGER BILLING)